Thrombus age and tissue plasminogen activator mediated thrombolysis in rats

Loren, Michael L.; Frade, L.J. García; Torrado, Mario; Navarro, José Luís

doi:10.1016/0049-3848(89)90009-1

Cited by 34 publications

(21 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Indeed, animal studies have shown that t-PA is most effective in immature clots. 41 Moreover, at later stages of CRVO with collateral vessel development, the t-PA injected into the occluded vein would follow the path of least resistance and be flushed out of the vein through the collateral vessels, leaving no t-PA to act on the thrombus. 27 Therefore, REF should ideally be performed soon after the onset of CRVO, when the thrombus is still immature and before the development of collateral vessels.…”

Section: Discussionmentioning

confidence: 99%

The Rationale of Retinal Endovascular Fibrinolysis in the Treatment of Retinal Vein Occlusion

Pournaras

Petropoulos²,

Pournaras³

et al. 2012

Retina

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

The Rationale of Retinal Endovascular Fibrinolysis in the Treatment of Retinal Vein Occlusion

Pournaras

Petropoulos²,

Pournaras³

et al. 2012

Retina

View full text Add to dashboard Cite

show abstract

“…This is similar to clot production methods used in imaging studies by Cheng et al (2005), Winter et al (2005) and Yu et al (2000). The clots were incubated for three hours at 37°C and refrigerated at 5°C for three days, ensuring maximal clot retraction, lytic resistance and stability (Francis et al 1995;Loren et al 1989;Meunier et al 2007;Shaw et al 2006).Before each experiment, the micropipette was removed to produce a cylindrical clot adherent to the suture. The clot was typically 5-8 l in volume and approximately 300 m in width.…”

Section: Methodsmentioning

confidence: 99%

Tissue Plasminogen Activator Concentration Dependence of 120 kHz Ultrasound-Enhanced Thrombolysis

Shaw

Meunier

Lindsell

et al. 2008

Ultrasound in Medicine & Biology

View full text Add to dashboard Cite

It has been known for some time that the application of ultrasound can enhance the efficacy of thrombolytic medications such as recombinant tissue plasminogen activator (rt-PA). Potential clinical applications of this ultrasound-enhanced thrombolysis (UET) include the treatment of myocardial infarction, acute ischemic stroke, deep venous thrombosis and other thrombotic disorders. It may be possible to reduce the dose of rt-PA while maintaining lytic efficacy; however there is little data on the rt-PA concentration dependence of UET. In this work, the rt-PA concentration dependence of clot lysis resulting from 120 kHz UET exposure was measured in an in vitro human clot model. Clots were exposed to rt-PA for 30 min, with (UET treated) or without 120 kHz ultrasound (rt-PA treated) at 37 degrees C, and the clot width measured as a function of time. The rt-PA concentration ranged from 0-10 microg/mL. The initial lytic rate for the UET-treated group was greater than that of the rt-PA group at almost all rt-PA concentrations, and exhibited a maximum over concentration values of 1-3 microg/mL.

show abstract

“…In acute myo cardial infarction, the success rate of thrombolytic ther apy diminishes with time after onset (19), probably due to progressive cross-linking of the fibrin network (20). There fore, coronary artery recanalization should be accom plished as rapidly as possible, thus leading to improve ment of left ventricular function and reduction of mortal ity (21).…”

Section: Discussionmentioning

confidence: 99%

Thrombolytic Activity of a Novel Modified Tissue-Type Plasminogen Activator, YM866, in a Canine Model of Coronary Artery Thrombosis

Kawasaki¹,

Katoh²,

Kaku³

et al. 1993

Japanese Journal of Pharmacology

View full text Add to dashboard Cite

ABSTRACT-The thrombolytic activity of a novel modified t-PA, YM866, was compared with that of a recombinant t-PA in a canine model of copper coil-induced coronary thrombosis. The coronary thrombus was allowed to age for 1, 3 or 6 hr before either drug was administered. YM866 was administered by i.v. bolus injection, while t-PA was given by the same method, as well as by 60-min i.v. infusion. YM866 show ed thrombolytic activity 2 to 4 times as potent as that of t-PA when administered by bolus injection, the difference in thrombolytic effect being obvious in the 3 and 6-hr-old thrombi. Coronary reperfusion was achieved more rapidly with YM866 than with i.v. infusion of t-PA. In animals injected with doses of more than 0.1 mg/kg of YM866, no acute reocclusion occurred. Depletion of plasma fibrinogen to 70% of baseline levels was observed in animals given 0.2 mg/kg YM866, 0.4 mg/kg t-PA by bolus, and 0.6 mg/kg t-PA via infusion. The residual plasma YM866 and t-PA antigen 30 min after bolus injection was 2570 and 310 of the peak levels, respectively. YM866, administered by i.v. bolus injection, was thus confirmed to exert a thrombolytic effect superior to that of bolus injection and infusion of t-PA, without systemic fibrinolytic activation. These results suggest the potential clinical applicability of YM866 as a thrombolytic agent that can be administered by i.v.bolus injection for acute myocardial infarction.

show abstract

Thrombus age and tissue plasminogen activator mediated thrombolysis in rats

Cited by 34 publications

References 15 publications

The Rationale of Retinal Endovascular Fibrinolysis in the Treatment of Retinal Vein Occlusion

The Rationale of Retinal Endovascular Fibrinolysis in the Treatment of Retinal Vein Occlusion

Tissue Plasminogen Activator Concentration Dependence of 120 kHz Ultrasound-Enhanced Thrombolysis

Thrombolytic Activity of a Novel Modified Tissue-Type Plasminogen Activator, YM866, in a Canine Model of Coronary Artery Thrombosis

Contact Info

Product

Resources

About